Israel Englander Viridian Therapeutics, Inc.\De Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Millennium Management LLC holds 365,972 shares of VRDN stock, worth $5.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

365,972

Previous 668,036 45.22%

Holding current value

$5.83 Million

Previous $15.2 Million 53.84%

% of portfolio

0.0%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$17.85 - $25.71 $5.39 Million - $7.77 Million	-302,064 Reduced 45.22%	365,972 $7.02 Million
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $5.35 Million - $10.3 Million	439,854 Added 192.76%	668,036 $15.2 Million
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.26 $2.41 Million - $3.59 Million	207,711 Added 1014.66%	228,182 $2.97 Million
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $3.49 Million - $4.87 Million	-204,318 Reduced 90.89%	20,471 $358,000
Q4 2023 Feb 14, 2024	SELL	$11.12 - $22.5 $12.4 Million - $25 Million	-1,112,999 Reduced 83.2%	224,789 $4.9 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $16.3 Million - $21.5 Million	723,699 Added 117.85%	1,337,788 $31.8 Million
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $4.3 Million - $6.46 Million	-171,765 Reduced 21.86%	614,089 $15.6 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $446,851 - $707,633	23,794 Added 3.12%	785,854 $23 Million
Q3 2022 Nov 14, 2022	SELL	$10.7 - $25.5 $3.9 Million - $9.28 Million	-364,025 Reduced 32.33%	762,060 $15.6 Million

Others Institutions Holding VRDN

# of Institutions

200

Shares Held

79.4M

Call Options Held

477K

Put Options Held

917K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $636M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account